AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Earnings in 4d

APMD · NASDAQ · Biotechnology

Apnimed

Develops Oxnimbi, an oral therapy under FDA review for obstructive sleep apnea.

$30.30

After-hours close+0.57 (+1.92%)

At close$29.73(+3.52%)

Something off on this page? Send us feedback.

Breakdown13F · Form 4

Institutions —Insiders —

Shares outstanding 39.82M · Float 3.22M · 8.1% free float

Top shareholders13F · 13D/G · Form 4

No 13F, 13D/G or Form 4 holder on record.

Institutions13F

No 13F holders on record.

Beneficial owners13D/G · 5% or more, as filed

No 13D/G filer at 5% or more on record.

InsidersForm 4

Latest trades

Nothing filed in the last 12 months.

CongressHouse and Senate disclosures

Not reported.